Skip to content
Homepage
Author:
OSR Health, Inc.
Posted Date:
August 11, 2026
OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development
OSR Health, Inc.
August 11, 2026
OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program
OSR Health, Inc.
August 7, 2026
Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform
OSR Health, Inc.
August 3, 2026
OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment
OSR Health, Inc.
July 31, 2026
OSR Health, A Message From the CEO
OSR Health, Inc.
July 13, 2026
CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
OSR Health, Inc.
July 2, 2026
Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
OSR Health, Inc.
July 2, 2026
OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares
OSR Health, Inc.
June 25, 2026
OSR Holdings Is Now OSR Health – A New Name That Says Exactly What We Do
OSR Health, Inc.
June 22, 2026
